← Search & browse all drugs
CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › Fibrates
simfibrate
C10AB06
Adult Dosing
- 250 mg orally 2 to 3 times daily with meals
Pediatric Dosing
- Safety and efficacy in pediatric patients not established
Indications
- Treatment of hyperlipidemia (hypercholesterolemia and hypertriglyceridemia)
Mechanism of Action
- Fibrate derivative that activates peroxisome proliferator-activated receptor alpha (PPAR-alpha), decreasing hepatic triglyceride synthesis, increasing VLDL clearance, and modestly increasing HDL levels
Contraindications
- Severe hepatic impairment
- Pre-existing gallbladder disease
- Severe renal impairment
- Known hypersensitivity to fibrates
Adverse Reactions
- Gastrointestinal distress (dyspepsia, nausea, abdominal pain)
- Myalgia and creatine phosphokinase elevation
- Elevated transaminases
- Increased risk of cholelithiasis
Drug Interactions
- Increased risk of myotoxicity and rhabdomyolysis when combined with HMG-CoA reductase inhibitors (statins)
- Enhanced anticoagulant effect with coumarin anticoagulants, requiring frequent INR monitoring
Curated Content: Needs Vetting Before Put to Clinical Use